Structural Biology and Integrated drug discovery services

Our cutting-edge technology platform and extensive experience in structural biology and drug discovery will significantly accelerate your discovery project.

Your Trusted Partner in Structural Biology & Drug Discovery

SARomics Biostructures provides structural biology and integrated drug discovery services to the biotech industry, large pharmaceutical companies, and academic groups. The company was established in 2006 as a research-focused contract research organization (CRO) by scientists with extensive experience in structural biology and structure-based drug design. It rapidly gained recognition as a leading service provider across North and South America, Asia, Europe, Scandinavia, and Australia. Our comprehensive range of outsourcing services is backed by a state-of-the-art technology platform that ensures the success of your project.
An overview of our services is provided below.

Looking for career opportunities?
Visit our career page and find out!

Discover how SARomics Biostructures can benefit you

Explore our cutting-edge technology platform and extensive services in structural biology and integrated drug discovery

X-ray crystallography has played a crucial role in advancing our understanding of structural biology, including protein structure and function, as well as in the discovery and development of new drugs. Our high-throughput X-ray crystallography services pipeline is based on our FastLane™ Premium and FastLane™ Standard libraries, and it offers over 500 verified drug targets that are ready to be crystallized with your chosen ligand (FastLane™ Premium) or expressed, purified, and crystallized according to verified protocols (FastLane™ Standard) with a turnaround time of a few weeks. We use in-house expression systems in our gene-to-structure pipeline. Our close proximity to the BioMax X-ray beamline at the MAX IV synchrotron laboratory in Lund provides us with considerable flexibility in beamline access and X-ray data collection, thus enabling rapid structure elucidation services. Please view our knowledge center for details of our crystallization and crystallography workflow. For examples of projects we have contributed to, please visit our publications page.


Thanks to advancements in NMR instrumentation over the past few decades, this method has become a central tool in structural biology and drug discovery. It is particularly useful for determining the structure of small flexible proteins and peptides, as well as for exploring protein-ligand interactions. Our access to high-quality, state-of-the-art NMR spectroscopy instrumentation allows us to offer comprehensive peptide and protein NMR spectroscopy (BioNMR) services for protein structure determination and fragment screening. Below is a list of our service packages, which can be tailored to the specific needs of any project.

  • Peptide NMR & protein NMR assignment, secondary structure assessment
  • Peptide NMR & protein NMR structure determination
  • Protein-ligand & protein-protein complex structure determination
  • Fragment screening using 1D or 2D NMR spectroscopy
  • Epitope mapping and dissociation constant (Kd) determinations for compounds
  • Higher order structure (HOS) comparability analysis of biosimilars, formulation characterization and optimization
  • Expression and purification of 2H, 15N, and 13C-labelled protein in E.coli for NMR spectroscopy studies and structure determination

The contribution of structural biology to our understanding of the basic principles of antibody structure and function and to the discovery and development of new biological drugs cannot be overestimated. SARomics Biostructures has built up a team with a high level of experience and expertise in analyzing monoclonal antibodies, antibody-antigen complex structures, and comparability analysis of biosimilars using X-ray crystallography and NMR spectroscopy. Our services for studying the structural characteristics and comparability of biosimilars’ higher-order structure (HOS) use 13C-natural abundance 2D-NMR spectroscopy and are fast and cost-efficient (see our blog article on NMR in comparability studies). Our monoclonal antibody structure services can assist with the following:

  • Epitope definition to file stronger IP
  • Understanding the mode of action
  • Structure-based antibody engineering: affinity maturation, humanization, antibody-drug conjugates (ADC), etc.
  • Structural characterization of protein drugs for regulatory purposes

SARomics Biostructures, in collaboration with our partner, Read Glead Discovery, runs an integrated lead discovery platform. This platform enables hit identification, hit validation, and lead generation for a variety of protein targets. At the platform’s core is our proprietary weak affinity chromatography (WAC™), a cost-efficient, high-throughput technique for fragment screening and hit identification. Over the past 7 years, we have gained extensive experience in creating high-quality starting points for structure-based hit-to-lead optimization programs (see our blog post on WAC™). Our focus has been on driving the project through lead optimization to candidate drug generation. Some advantages of the WAC™ technique include:

  • Robust and accurate (validated against NMR spectroscopy and X-ray crystallography)
  • Quick set-up and workflow (3 weeks turnaround)
  • High throughput (>5000 cmpds/week)
  • Low material consumption (<5 mg protein)
  • Find mM hits by screening fragments at low concentrations (1-5 μM)
  • Hit rates from 1% to 20%, (avg 6%)

Please visit our methods and knowledge center for discussion of different strategies in structure-based drug design.

Crystallization-Grade Recombinant Proteins For Research And Analytic Purposes

Our comprehensive catalog features high-purity, crystallization-grade drug-target recombinant proteins meticulously expressed and purified to the highest standards in our cutting-edge protein lab. These proteins have undergone rigorous characterization using biophysical methods, and their suitability for crystallization has been unequivocally validated.

Make sure not to miss our featured blog posts!

WAC™ Screening Technology

In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.

2023 – More Structural Biology & Drug Discovery

In this article discuss some representative projects and company business development activities from 2023.